Allocations
Mad Rabbit, a California-based tattoo aftercare brand, has raised USD2 million in a seed funding round led by Acronym Venture Capital with participation from Mark Cuban and Stefon Diggs.
The brand is committed to reinventing the tattoo skincare industry with its high-quality, all natural products. With this funding, Mad Rabbit will continue to expand its experiential lifestyle brand and optimize its product offerings, manufacturing, and operations, and marketing efforts.
“In 2019, we were selling tattoo balm from our dorm rooms, and in just two short years, we’ve successfully inked a deal with Mark Cuban and are now primed for even
Kraken Resources II (Kraken II) has received an equity commitment in excess of USD400 million from funds managed by Kayne Anderson Capital Advisors (Kayne Anderson), including Kayne Anderson Energy Fund VIII (KAEF VIII) and Kayne Private Energy Income Fund II (KPEIF II), along with Kraken II’s management team.
Headquartered in Houston, Texas, Kraken II is a private oil and gas company formed to pursue large, oil-weighted acquisitions with an initial focus in the Williston Basin. The Company will target assets that have a significant existing production component and a multi-year inventory of development locations the Kraken II team can exploit.
King River Capital (King River), a technology-focused venture capital firm with offices in Sydney and the US, has held the first close of its second fund (KRC Fund 2), securing commitments of USD95million.
KRC Fund 2 investors include numerous technology entrepreneurs and leaders from companies such as Xero, AfterPay, Mirror, and Palantir, reflecting King River’s strong network of relationships across the industry in both Australia and the US. Other investors include leading institutions and family offices such as Ariadne Australia, Belfer Management and Marinya Capital. The firm is expecting full participation in Fund 2 from existing Fund 1 investors.
KRC
Six months after raising USD7 million in seed funding, Paris-based data-centric AI training platform Kili Technology has raised USD25 million in Series A financing from London-based venture capital fund Balderton Capital and further commitment from initial investors, Serena Capital and Headline.
“Managing and transforming unstructured data into training-ready data involves complex workflows and collaboration between business users and data teams. Kili’s data infrastructure platform simplifies this by managing the entire data lifecycle, helping companies to save time and money. We were impressed by the combination of technical experience from Kili’s team and their capacity to execute at a fast pace,”
Standard Chartered Bank and Intermediate Capital Group (ICG) have successfully closed an initial EUR1.45 billion ESG-linked subscription facility for ICG Europe Fund VIII. The lending group comprises Standard Chartered Bank, BNP Paribas, ANZ Banking Group Limited, ING Bank, and Royal Bank of Canada.
The facility will serve as a key source of liquidity for the Fund, which is dedicated to investing in mid to upper middle market European businesses.
ICG recognises that environmental, social and governance issues can be a key driver of investment value and that investors have a vital and unique role to play in supporting private companies
UK mid-market private equity firm Graphite Capital has acquired Wonderbly, a publishing platform for personalised children’s books. The company is also developing personalised products for third-party clients.
As a digital, direct-to-consumer publisher, Wonderbly sells its books in more than 150 countries, with international sales accounting for over 85 per cent of its revenues. The company sold more than one million books in 2020 and, in May this year, won ‘Children’s Publisher of the Year’ at the British Book Awards.
At the heart of Wonderbly’s success and growth is its unique operating model – a fully integrated approach to creating,
Alva, a stakeholder intelligence platform has partnered with Ballast Research and Hamilton Place Strategies (HPS). The partnership was supported by a majority investment in alva by Falfurrias Capital Partners (FCP), formalising the relationship between the leaders across corporate stakeholder management. The partnership and investment follows FCP’s earlier majority investments in Ballast Research and HPS.
Headquartered in London, UK, alva is a stakeholder intelligence platform that provides data-rich, real-time technology to companies across industries, including financial services, consumer, healthcare, and professional services. Built on award-winning Natural Language Processing technology, alva delivers the richest and most accurate insights based on the analysis
Eurazeo has held the final close of Idinvest Private Debt V, its fifth direct lending fund, at EUR1.5 billion, ahead of its initial EUR1.2 billion target.
Along with the Group’s EUR500 million in private debt funds and investment mandates, its current private debt programme now totals EUR2.0 billion.
Building on the solid track record of its four previous vintages of direct lending vehicles, this fund was raised thanks to the renewed confidence of Eurazeo’s long-standing investors, while also attracting many new investors. Today, more than 70 per cent of the fund’s investors are located outside France.
Eurazeo’s Private
Ardian has arranged a unitranche facility with the participation of a wholly-owned subsidiary division of Caisse de dépôt et placement du Québec (CDPQ), to support the investment of Naxicap Partners in Lagarrigue, a global specialist in large scale external orthopaedic devices for the treatment of disabilities, alongside the Company’s management.
Headquartered in Toulouse and founded in 1976, the French-based Group has extended its presence since 2016 into neighbouring countries, such as Belgium, Switzerland and Spain. This development was enabled by an active acquisition strategy, which now results in over 30 per cent of its sales being achieved internationally.
Together with
Artios Pharma Limited (Artios), a DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, has completed a USD153 million (GBP110 million) Series C financing to fund further development of its clinical-stage pipeline.
The oversubscribed financing was co-led by Omega Funds and TCG X. Additional investors include Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments LP, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital. These new investors join existing investors Arix Bioscience
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
